E13632 Background: Aurora B kinase is involved in coordinating multiple steps of mitosis, including chromosome condensation, chromosome segregation and cytokinesis. These essential functions of Aurora B and its over-expression in multiple cancer types render this serine/threonine kinase an attractive target for therapeutic intervention. Methods: Inhibition of cell proliferation was tested in Alamar blue and thymidine incorporation assays. Cell-cycle status was determined by DNA content analysis (FACS, Cellomics). Apoptosis was analyzed by Western blotting for cleaved PARP and assessment of nuclear fragmentation by microscopy of DAPI-stained cells. Senescence was detected by staining for SA-beta-Gal activity. Nude mice were grafted s.c. with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) tumor cells (cell lines Calu-6 and HCT116, respectively). BI 811283 was administered once weekly to mice bearing established tumors by 24 h s.c. infusion using osmotic mini-pumps. In this schedule, the maximum tolerated dose (MTD) was determined as 20 mg/kg. Results: BI 811283 potently inhibited Aurora B kinase (IC50 = 9 nM) and blocked the proliferation of cells of diverse origin in a panel of 24 cancer cell lines (all EC50 <14 nM). In the four cell lines tested by FACS, the fraction of polyploid cells increased by up to 80% within 48 h, with changes up to 80%. In NCI-H460 cultures, ∼25% of the cells became senescent within 96 h, whereas concomitant hallmarks of apoptosis were only observed in a smaller percentage (7% after 96 h). In nude mouse xenograft models of human NSCLC and CRC, BI 811283 dose-dependently inhibited tumor growth and, at the MTD, tumor regression was observed in a subset of animals. Histological examination of treated tumors showed an accumulation of enlarged, multinucleated cells in accordance with the expected mechanism of action. Conclusions: BI 811283 is a potent Aurora kinase inhibitor that induces mitotic checkpoint override, resulting in nonproliferating, polyploid, and senescent tumor cells. Aurora B inhibition defines a new mechanistic paradigm for M-phase targeting agents.